EUmergency! GSK merges EU and emerging markets businesses amid sales slump
This article was originally published in Scrip
GlaxoSmithKline's second quarter pharmaceuticals and vaccines sales were down by 6% to £1.67 billion in the US. In Europe, turnover dropped 8% to £1.24 billion, a performance that has prompted GSK to combine its European and Emerging Markets business units under a single commercial structure. Significantly perhaps, the combined unit will be led by Abbas Hussain who is currently president of Emerging Markets and Asia Pacific.